



PRESS RELEASE

For Immediate Release

**Corgenix to Exhibit AspirinWorks® Test
at ADA 2008 Meeting in San Francisco**

DENVER — June 4, 2008 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, is exhibiting its AspirinWorks® Test at the American Diabetes Association's 68th Scientific Sessions. The exhibits are open Saturday through Monday, June 7 – 9, 2008, at the Moscone Convention Center in San Francisco, Calif.

This marks the first time the AspirinWorks test will be exhibited at the American Diabetes Association (ADA) Scientific Sessions. Corgenix representatives will be on-hand during the conference at booth 738 to answer questions about the AspirinWorks Test, including ongoing clinical research and the relationship among diabetes, aspirin effect and cardiovascular disease.

Corgenix is presenting an abstract on aspirin effect and diabetes during the general poster session on Saturday, June 7 in Hall D from 11:30 a.m. until 1:30 p.m. The abstract examines possible differences between healthy and diabetic men and women in heart attack and stroke risk reduction based on their response to the anti-clotting effects of aspirin.

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at www.aspirinworks.com.

It is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type of aspirin is appropriate for them to achieve the most benefit with the fewest side effects.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Field Code Changed

Media Contact:
Dan Snyders
Vice President, Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
dan@armadamedical.com

